Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
One prototype award will fund development of an FDA-cleared or FDA-approved wound barrier combination product with antimicrobial and/or antifungal activity to prevent battlefield wound infection.
⚑ Federal contract solicitation under prototype Other Transaction Authority (pOTA); one award will be made. · Requires a final product that already has FDA approval or clearance. · Applicant restrictions apply, but the notice does not identify a class eligible for direct university application; treat as ineligible for direct university submission absent a qualifying prime contractor role. · Amendment 0003 extends the proposal due date; another amendment will post Q&A/responses.
Unit fits — one characterization, each unit's own rules
| Tom Love Innovation Hub | 60 good | funds commercialization; prototyping/demonstration stage; deep-tech content |
| IPPRA | 15 none | university cannot apply directly (ineligible) |
| Physical Sciences & Engineering (demo) | 15 none | university cannot apply directly (ineligible) |
Description
This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022. NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date).
Eligibility
Applicant restrictions (federal contract). Set-aside: . Notice type: Solicitation. Organization: DEPT OF DEFENSE / DEFENSE HEALTH AGENCY (DHA) / DEFENSE HEALTH AGENCY.
Apply
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →
Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.